Home
Conditions
Lymphoma, T-Cell

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

694 public trials 105 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Recruiting

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

NCT05518851

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Peking University Third Hospital Beijing, Beijing Municipality, China

SUN YAI-SEN Memorial Hospital, SUN YAI-SEN University Guandong, Guangdong, China

Hospital for Skin Disease, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College Nanjing, Jiangsu, China

Qilu Hospital of Shandong University Jinan, Shandong, China

View Trial Details

Recruiting

Transplantation After Complete Response In Patients With T-cell Lymphoma

NCT05444712

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Chu D'Amiens - Hopital Sud Amiens, France

Chu D'Angers Angers, France

Ch Victor Dupouy Argenteuil, France

Ch D'Avignon - Hopital Henri Duffaut Avignon, France

View all 48 locations

View Trial Details

Recruiting

Go-CHOP as the Frontline Therapy for PTCL

NCT05963347

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Henan Cancer Hospital Zhengzhou, Henan, China

View Trial Details

Recruiting

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

NCT05833893

Conditions: Advanced Lymphoma, Lymphoma, Lymphoma, Extranodal NK-T-Cell, +6 more
Locations: ChinaPLAGH Beijing, Haidian, China

View Trial Details

Recruiting

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

NCT04922567

Conditions: CHOP, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations: 2nd Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, Zhejiang, China

View Trial Details

Enrolling by Invitation

Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash

NCT06665490

Conditions: Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Northwestern University Department of Dermatology Chicago, Illinois, United States

View Trial Details

Enrolling by Invitation

BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas

NCT07258680

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

NCT07729397

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Diffuse Large B-Cell Lymphoma (DLBCL), +17 more
Locations: Houston Methodist Hospital Houston, Texas, United States

View Trial Details

Not Yet Recruiting

Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases

NCT07727083

Conditions: Aggressive NK-cell Leukemia, DNA Virus Infections, Epstein-Barr Virus Infections, +24 more
Locations: Fudan University Shanghai Cancer Center Shanghai, Shanghai Municipality, China

View Trial Details

Not Yet Recruiting

Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)

NCT07717580

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Peking University First Hospital Beijing, Beijing Municipality, China

View Trial Details

Lymphoma, T-Cell

Lymphoma, T-Cell trial results

Related conditions